LIMINATUS PHARMA INC-CL A (LIMN) Stock Overview
NASDAQ:LIMN - US53271X1081 - Common Stock
LIMN Key Statistics, Chart & Performance
The current stock price of LIMN is 3.41 USD. In the past month the price decreased by -60.85%.
LIMN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.00B | ||
| AMGN | AMGEN INC | 13.47 | 157.94B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.77B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 63.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.78 | 33.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| INSM | INSMED INC | N/A | 25.02B | ||
| NTRA | NATERA INC | N/A | 22.61B | ||
| BIIB | BIOGEN INC | 8.7 | 20.41B |
Related stock screener links
About LIMN
Company Profile
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
Company Info
LIMINATUS PHARMA INC-CL A
6 Centerpointe Dr., #625
La Palma CALIFORNIA US
Employees: 0
Phone: 12132735453
LIMINATUS PHARMA INC-CL A / LIMN FAQ
What is the stock price of LIMINATUS PHARMA INC-CL A today?
The current stock price of LIMN is 3.41 USD. The price increased by 22.66% in the last trading session.
What is the ticker symbol for LIMINATUS PHARMA INC-CL A stock?
The exchange symbol of LIMINATUS PHARMA INC-CL A is LIMN and it is listed on the Nasdaq exchange.
On which exchange is LIMN stock listed?
LIMN stock is listed on the Nasdaq exchange.
How many employees does LIMINATUS PHARMA INC-CL A have?
LIMINATUS PHARMA INC-CL A (LIMN) currently has 0 employees.
Should I buy LIMINATUS PHARMA INC-CL A (LIMN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LIMN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LIMN, evaluating the profitability, health, valuation and growth aspects
- LIMINATUS PHARMA INC-CL A (LIMN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LIMINATUS PHARMA INC-CL A (LIMN) Sales and EPS estimates to see what analysts future expectations are.
- LIMINATUS PHARMA INC-CL A (LIMN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LIMINATUS PHARMA INC-CL A (LIMN) Insider and Institutional Ownership to learn about the owners and their transactions.
- LIMINATUS PHARMA INC-CL A (LIMN) Stock Chart to make your own analysis
- LIMINATUS PHARMA INC-CL A (LIMN) Latest news and press-releases to stay up to date.
Does LIMINATUS PHARMA INC-CL A (LIMN) stock pay dividends?
LIMN does not pay a dividend.
What is the Price/Earnings (PE) ratio of LIMINATUS PHARMA INC-CL A (LIMN)?
LIMINATUS PHARMA INC-CL A (LIMN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.35).
LIMN Technical Analysis
LIMN Financial Highlights
Over the last trailing twelve months LIMN reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS decreased by -288.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.22% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |